Gregory Friberg
Executive VP and Chief Research & Development OfficerDr. Gregory Friberg, also known as Greg, M.D., is Executive VP and Chief Research & Development Officer at BioMarin Pharmaceutical Inc. since September 30, 2024. He Joined BioMarin Pharmaceutical Inc. since September 30, 2024.He was Head of Oncology Global Development of Amgen Inc. He worked for Amgen, Inc., where he most recently served as Vice President, Global Medical Affairs, Rare Disease. Dr. Friberg brings a wealth of experience in clinical development and lifecycle management to the role. During his 18 years at Amgen, he has been responsible for advancing multiple medicines from investigational new drug application filing through late-stage development. In addition, he served as head of Global Development for the company's hematology/oncology and bone portfolios. Dr. Friberg holds an M.D. from New York Medical College. He completed his residency in internal medicine at Dartmouth-Hitchcock Medical Center and his fellowship in hematology and oncology at The University of Chicago Medical Center. Prior to Amgen, he served on the faculty of the University of Chicago.
Positions
- Company NameBioMarin Pharmaceutical Inc.Stock CodeBMRNPositionExecutive VP and Chief Research & Development OfficerColleagues
- AHAlexander HardyPresident, CEO & Director
- ITIan T. ClarkIndependent Chair of the Board
- BRBrian R. MuellerCFO & Executive VP of Finance
- CGC. Greg GuyerExecutive VP & CTO
- CHCristin HubbardExecutive VP & Chief Commercial Officer
- RJRobert J. HombachIndependent Director
- EMElizabeth McKee AndersonIndependent Director
- MJMark Joseph EnyedyIndependent Director
